Hutchison China MediTech Limited (HCM): Price and Financial Metrics
GET POWR RATINGS... FREE!
HCM POWR Grades
- Sentiment is the dimension where HCM ranks best; there it ranks ahead of 90.29% of US stocks.
- The strongest trend for HCM is in Value, which has been heading up over the past 31 weeks.
- HCM's current lowest rank is in the Quality metric (where it is better than 8.18% of US stocks).
HCM Stock Summary
- Of note is the ratio of HUTCHMED (China) Ltd's sales and general administrative expense to its total operating expenses; just 12.72% of US stocks have a lower such ratio.
- HCM's price/sales ratio is 18.64; that's higher than the P/S ratio of 89.1% of US stocks.
- With a year-over-year growth in debt of 393.03%, HUTCHMED (China) Ltd's debt growth rate surpasses 96.86% of about US stocks.
- Stocks that are quantitatively similar to HCM, based on their financial statements, market capitalization, and price volatility, are OCFT, TARO, AUMN, VNE, and NEON.
- Visit HCM's SEC page to see the company's official filings. To visit the company's web site, go to www.hutch-med.com.
HCM Stock Price Chart Interactive Chart >
HCM Price/Volume Stats
|Current price||$29.94||52-week high||$43.94|
|Prev. close||$29.73||52-week low||$23.67|
|Day high||$31.15||Avg. volume||315,284|
|50-day MA||$32.79||Dividend yield||N/A|
|200-day MA||$33.63||Market Cap||5.18B|
Hutchison China MediTech Limited (HCM) Company Bio
Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in China. The company was founded in 2000 and is based in Hong Kong, Hong Kong.
Most Popular Stories View All
HCM Latest News Stream
|Loading, please wait...|
HCM Latest Social Stream
View Full HCM Social Stream
Latest HCM News From Around the Web
Below are the latest news stories about HUTCHMED (China) Ltd that investors may wish to consider to help them evaluate HCM as an investment opportunity.
HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US. Further details of the presenta
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, for the treatment of chronic adult primary immune thrombocytopenia (“ITP”) patients who have received at le
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China
— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 that also target the B-cell receptor (“BCR”) signaling pathway, and tazemetostat and HMPL-306 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) has initiated a Phase
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series (“GEIS”) in its quarterly review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The inclusions come into effect on Monday, December 20, 2021. FTSE Russell is a global index leader that provid
Investment company Virtus AllianzGI International Small-Cap Fund (Current Portfolio) buys Alchip Technologies, Sojitz Corp, Bystronic AG, Industrial & Infrastructure Fund Investment Corp, JMDC Inc, sells Marui Group Co, HELLA GmbH KGaA, OC Oerlikon Corp AG, Pfaffikon, Showa Denko KK, Open House Co during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Virtus AllianzGI International Small-Cap Fund.
HCM Price Returns
Continue Researching HCMWant to see what other sources are saying about Hutchison China MediTech Ltd's financials and stock price? Try the links below:
Hutchison China MediTech Ltd (HCM) Stock Price | Nasdaq
Hutchison China MediTech Ltd (HCM) Stock Quote, History and News - Yahoo Finance
Hutchison China MediTech Ltd (HCM) Stock Price and Basic Information | MarketWatch